Codexis Inc. has announced the signing of a lease for a new 34,000 square foot GMP manufacturing facility in Hayward, California. This expansion will enable the company to increase its capabilities in the GMP manufacturing of siRNA and other oligonucleotides using its ECO Synthesis platform. The facility, designed for flexibility, will also support the production of high-quality purified enzymes. Modifications to the facility are expected to begin in early 2026, underscoring Codexis's commitment to supporting early clinical trials and adapting to evolving business needs.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Codexis Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9572153-en) on November 10, 2025, and is solely responsible for the information contained therein.